

Rocchina Lucia Colucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3637550/publications.pdf>

Version: 2024-02-01

113
papers

4,316
citations

81743

39
h-index

149479

56
g-index

114
all docs

114
docs citations

114
times ranked

5599
citing authors

#	ARTICLE	IF	CITATIONS
1	Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. <i>Acta Neuropathologica</i> , 2018, 136, 345-361.	3.9	167
2	Adenosine and inflammation: what's new on the horizon?. <i>Drug Discovery Today</i> , 2014, 19, 1051-1068.	3.2	139
3	Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders. <i>Current Drug Targets</i> , 2012, 13, 842-862.	1.0	128
4	Review article: molecular, pathological and therapeutic features of human enteric neuropathies. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 25-42.	1.9	111
5	Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications. , 2008, 120, 233-253.		103
6	Vascular Generation of Tumor Necrosis Factor- α Reduces Nitric Oxide Availability in Small Arteries From Visceral Fat of Obese Patients. <i>Journal of the American College of Cardiology</i> , 2011, 58, 238-247.	1.2	98
7	Endothelial Dysfunction in Small Arteries of Essential Hypertensive Patients. <i>Hypertension</i> , 2013, 62, 337-344.	1.3	97
8	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	6.1	97
9	Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 435-442.	1.3	96
10	Cyclooxygenase-2 Inhibition Improves Vascular Endothelial Dysfunction in a Rat Model of Endotoxic Shock: Role of Inducible Nitric-Oxide Synthase and Oxidative Stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 945-953.	1.3	92
11	Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review. <i>Clinical Therapeutics</i> , 2009, 31, 1426-1453.	1.1	92
12	Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 318-327.	1.6	88
13	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. <i>Progress in Neurobiology</i> , 2020, 191, 101806.	2.8	87
14	Alteration of colonic excitatory tachykinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Journal of Neuroinflammation</i> , 2016, 13, 146.	3.1	77
15	Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by α_2 -adrenoceptors in the presence of experimental colitis. <i>British Journal of Pharmacology</i> , 2003, 139, 309-320.	2.7	74
16	Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin II-Infused Mice. <i>Hypertension</i> , 2007, 49, 679-686.	1.3	66
17	Atorvastatin Prevents Endothelial Dysfunction in Mesenteric Arteries From Spontaneously Hypertensive Rats. <i>Hypertension</i> , 2009, 53, 1008-1016.	1.3	62
18	Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. <i>World Journal of Gastroenterology</i> , 2005, 11, 4052.	1.4	61

#	ARTICLE	IF	CITATIONS
19	The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation and potential therapeutic applications. , 2013, 139, 157-188.		60
20	Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. British Journal of Pharmacology, 2005, 144, 338-348.	2.7	59
21	Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. Toxicology and Applied Pharmacology, 2004, 195, 62-72.	1.3	57
22	Pharmacological modulation of adenosine system: Novel options for treatment of inflammatory bowel diseases. Inflammatory Bowel Diseases, 2008, 14, 566-574.	0.9	57
23	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. Parkinsonism and Related Disorders, 2015, 21, 1407-1414.	1.1	56
24	Microvascular Endothelial Dysfunction in Human Obesity: Role of TNF- α . Journal of Clinical Endocrinology and Metabolism, 2019, 104, 341-348.	1.8	54
25	Platelet Serotonin Transporter in Patients With Diarrhea-Predominant Irritable Bowel Syndrome Both Before and After Treatment With Alosetron. American Journal of Gastroenterology, 2003, 98, 2705-2711.	0.2	53
26	Microvascular Endothelial Dysfunction in Patients with Obesity. Current Hypertension Reports, 2019, 21, 32.	1.5	53
27	Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug. Clinical Drug Investigation, 2002, 22, 799-818.	1.1	52
28	Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut, 2005, 54, 608-616.	6.1	52
29	Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 1194-1204.	0.6	50
30	Enteric Dysfunctions in Experimental Parkinsons Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 233-243.	1.3	49
31	The Blockade of Adenosine Deaminase Ameliorates Chronic Experimental Colitis through the Recruitment of Adenosine A _{2A} and A ₃ Receptors. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 434-442.	1.3	47
32	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. PLoS ONE, 2018, 13, e0195502.	1.1	47
33	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. Frontiers in Pharmacology, 2018, 9, 1094.	1.6	46
34	Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 79-87.	1.4	45
35	The β_3 -adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterology and Motility, 2008, 20, 1030-1041.	1.6	44
36	NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 86-95.	1.3	44

#	ARTICLE	IF	CITATIONS
37	The genetics of the serotonin transporter and irritable bowel syndrome. <i>Trends in Molecular Medicine</i> , 2008, 14, 295-304.	3.5	43
38	Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. <i>European Journal of Pharmacology</i> , 2011, 650, 639-649.	1.7	41
39	Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats. <i>PLoS ONE</i> , 2014, 9, e116253.	1.1	41
40	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1781-1791.	1.6	41
41	The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 179-191.	1.5	41
42	Aging Modulates the Influence of Arginase on Endothelial Dysfunction in Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2474-2483.	1.1	41
43	Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. <i>Pharmacological Research</i> , 2009, 59, 90-100.	3.1	40
44	Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. <i>Nutrition Research Reviews</i> , 2018, 31, 239-247.	2.1	40
45	A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 117-122.	0.9	39
46	Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2039-2050.	1.1	37
47	Influence of the Serotonin Transporter 5HTTLPR Polymorphism on Symptom Severity in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2013, 8, e54831.	1.1	37
48	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , 2018, 9, 1340.	1.6	35
49	Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 938-945.	1.3	34
50	Use of Selective Serotonin Reuptake Inhibitors during Pregnancy and Risk of Major and Cardiovascular Malformations: An Update. <i>Postgraduate Medicine</i> , 2010, 122, 49-65.	0.9	34
51	Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. <i>Pharmacological Research</i> , 2011, 63, 59-67.	3.1	34
52	Inducible Nitric Oxide Synthase Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries from Hypothyroid Rats. <i>Endocrinology</i> , 2009, 150, 1033-1042.	1.4	33
53	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. <i>Frontiers in Pharmacology</i> , 2018, 9, 1405.	1.6	33
54	Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. <i>British Journal of Pharmacology</i> , 2008, 155, 198-209.	2.7	31

#	ARTICLE	IF	CITATIONS
55	Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. <i>FASEB Journal</i> , 2020, 34, 5512-5524.	0.2	31
56	Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. <i>European Heart Journal</i> , 2015, 36, ehv365.	1.0	30
57	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , 2016, 104, 186-196.	3.1	30
58	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. <i>Purinergic Signalling</i> , 2017, 13, 497-510.	1.1	30
59	Effects of imidazoline derivatives on cholinergic motility in guinea-pig ileum: involvement of presynaptic $\alpha 2$ -adrenoceptors or imidazoline receptors?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1998, 357, 682-691.	1.4	29
60	Histamine H3 receptors mediate inhibition of noradrenaline release from intestinal sympathetic nerves. <i>British Journal of Pharmacology</i> , 2000, 129, 1387-1396.	2.7	29
61	Control of enteric neuromuscular functions by purinergic A_3 receptors in normal rat distal colon and experimental bowel inflammation. <i>British Journal of Pharmacology</i> , 2010, 161, 856-871.	2.7	29
62	An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 485-500.	1.6	29
63	Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. <i>British Journal of Pharmacology</i> , 2001, 132, 73-84.	2.7	28
64	Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. <i>European Heart Journal</i> , 2012, 33, 2225-2234.	1.0	28
65	Altered Expression Pattern of Molecular Factors Involved in Colonic Smooth Muscle Functions: An Immunohistochemical Study in Patients with Diverticular Disease. <i>PLoS ONE</i> , 2013, 8, e57023.	1.1	28
66	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. <i>Neurobiology of Disease</i> , 2020, 139, 104821.	2.1	28
67	Intestinal epithelial barrier and neuromuscular compartment in health and disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1564-1597.	1.4	28
68	Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. , 2010, 125, 62-78.		27
69	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , 2019, 43, 331-343.	1.6	27
70	Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. <i>Pharmacological Research</i> , 2005, 52, 485-490.	3.1	26
71	Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. <i>Digestive and Liver Disease</i> , 2009, 41, 395-405.	0.4	26
72	Role of the A_2B receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 1314-1329.	2.7	26

#	ARTICLE	IF	CITATIONS
73	Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colon. <i>Neurogastroenterology and Motility</i> , 2006, 18, 654-662.	1.6	25
74	A ₁ and A _{2a} receptors mediate inhibitory effects of adenosine on the motor activity of human colon. <i>Neurogastroenterology and Motility</i> , 2009, 21, 451-466.	1.6	24
75	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3523.	1.8	24
76	Characterization of β -adrenoceptor subtypes involved in the modulation of gastric acid secretion. <i>European Journal of Pharmacology</i> , 1995, 278, 179-182.	1.7	23
77	Clinical Efficacy of Esomeprazole in the Prevention and Healing of Gastrointestinal Toxicity Associated with NSAIDs in Elderly Patients. <i>Drugs and Aging</i> , 2008, 25, 197-208.	1.3	23
78	Glial A _{2B} Adenosine Receptors Modulate Abnormal Tachykinergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. <i>Cells</i> , 2020, 9, 1245.	1.8	20
79	Anti-inflammatory effect of a novel locally acting A _{2A} receptor agonist in a rat model of oxazolone-induced colitis. <i>Purinergic Signalling</i> , 2018, 14, 27-36.	1.1	19
80	Pathophysiology of Gastric Ulcer Development and Healing: Molecular Mechanisms and Novel Therapeutic Options. , 0, , .		18
81	Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P) ⁺ oxidase and COX-1. <i>British Journal of Pharmacology</i> , 2013, 169, 554-566.	2.7	18
82	Gastroprotective effects of pantoprazole against experimental mucosal damage. <i>Fundamental and Clinical Pharmacology</i> , 2000, 14, 89-99.	1.0	17
83	Derivatives of Benzimidazolquinoline and Benzimidazolisoquinoline as Selective A ₁ Adenosine Receptor Antagonists with Stimulant Activity on Human Colon Motility. <i>ChemMedChem</i> , 2011, 6, 1909-1918.	1.6	16
84	Adenosine pathway and cancer: where do we go from here?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 973-977.	1.5	16
85	Protective effects of the combination <i>Bifidobacterium longum</i> plus lactoferrin against NSAID-induced enteropathy. <i>Nutrition</i> , 2020, 70, 110583.	1.1	16
86	H ₃ receptor-mediated inhibition of intestinal acetylcholine release: pharmacological characterization of signal transduction pathways. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001, 363, 193-202.	1.4	15
87	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Neuropharmacology</i> , 2017, 123, 22-33.	2.0	15
88	Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Plays a Role in the Impairing Effects of Cyclooxygenase Inhibitors on Gastric Ulcer Healing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 140-149.	1.3	14
89	Role of peripheral GABAB receptors in the regulation of pepsinogen secretion in anaesthetized rats. <i>European Journal of Pharmacology</i> , 1995, 294, 191-200.	1.7	13
90	CCK1 and CCK2 receptors regulate gastric pepsinogen secretion. <i>European Journal of Pharmacology</i> , 1999, 373, 71-84.	1.7	13

#	ARTICLE	IF	CITATIONS
91	Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway. <i>British Journal of Pharmacology</i> , 2007, 151, 1246-1253.	2.7	13
92	Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. <i>Pharmacogenomics</i> , 2015, 16, 523-539.	0.6	13
93	The ecto-enzymes CD73 and adenosine deaminase modulate 5â€²-AMP-derived adenosine in myofibroblasts of the rat small intestine. <i>Purinergic Signalling</i> , 2018, 14, 409-421.	1.1	11
94	A holistic view of adenosine in the control of intestinal neuromuscular functions: the enteric â€œpurinomeâ€™ concept. <i>British Journal of Pharmacology</i> , 2011, 164, 1577-1579.	2.7	10
95	Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. <i>British Journal of Pharmacology</i> , 2014, 171, 3728-3740.	2.7	10
96	Effects of a bicarbonate-alkaline mineral water on digestive motility in experimental models of functional and inflammatory gastrointestinal disorders. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2008, 30, 261.	0.8	10
97	CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon. <i>European Journal of Pharmacology</i> , 2007, 557, 212-220.	1.7	9
98	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of dietâ€­induced obesity. <i>British Journal of Pharmacology</i> , 2021, 178, 3924-3942.	2.7	9
99	Suramin enhances ethanol-induced injury to gastric mucosa in rats. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1233-1241.	1.1	8
100	Acetylcholinesterase Blockade Does Not Account for the Adverse Cardiovascular Effects of the Antitumor Drug Irinotecan: A Preclinical Study. <i>Toxicology and Applied Pharmacology</i> , 2001, 177, 149-156.	1.3	8
101	Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 263-271.	2.3	6
102	Cyclooxygenase-2 Induction after Oral Surgery Does Not Entirely Account for Analgesia after Selective Blockade of Cyclooxygenase 2 in the Preoperative Period. <i>Anesthesiology</i> , 2006, 104, 152-157.	1.3	6
103	Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 379, 305-313.	1.4	5
104	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6325.	1.8	5
105	Pharmacological modulation of adenosine receptor pathways and inflammatory disorders: the way towards novel therapeutics?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 717-721.	1.9	4
106	Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. <i>Pharmacological Reports</i> , 2020, 72, 1347-1357.	1.5	4
107	Central administration of cholecystokinin stimulates gastric pepsinogen secretion from anaesthetized rats. <i>Neuroscience Letters</i> , 1995, 193, 13-16.	1.0	3
108	Determination on functional basis of presynaptic $\hat{1}\pm 2$ -adrenoceptor subtypes in guinea-pig duodenum. <i>Neuroscience Letters</i> , 1996, 210, 29-32.	1.0	3

#	ARTICLE	IF	CITATIONS
109	Central GABA-A receptors exert a tonic inhibitory control on gastric pepsinogen secretion in anaesthetized rats. <i>Autonomic and Autacoid Pharmacology</i> , 1995, 15, 187-196.	0.7	1
110	15 Altered Adenosine Signalling in the Presence of Bowel Inflammation: Role of $\alpha 2B$ Receptors in the Control of Colonic Motility. <i>Gastroenterology</i> , 2012, 142, S-4.	0.6	1
111	Response to Endothelial Nitric Oxide Synthase, Cyclooxygenase-2, and Essential Hypertension: Is There an Interaction?. <i>Hypertension</i> , 2013, 62, e16.	1.3	1
112	Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. <i>Gastroenterology</i> , 2017, 152, S180.	0.6	1
113	The role of serotonin and its pathways in gastrointestinal disorders. , 2021, , 67-94.		1